1219948-76-1Relevant articles and documents
Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532
Ushiyama, Fumihito,Takashima, Hajime,Matsuda, Yohei,Ogata, Yuya,Sasamoto, Naoki,Kurimoto-Tsuruta, Risa,Ueki, Kaori,Tanaka-Yamamoto, Nozomi,Endo, Mayumi,Mima, Masashi,Fujita, Kiyoko,Takata, Iichiro,Tsuji, Satoshi,Yamashita, Haruhiro,Okumura, Hirotoshi,Otake, Katsumasa,Sugiyama, Hiroyuki
, (2021)
Infectious diseases caused by resistant Gram-negative bacteria have become a serious problem, and the development of therapeutic drugs with a novel mechanism of action and that do not exhibit cross-resistance with existing drugs has been earnestly desired. UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) is a drug target that has been studied for a long time. However, no LpxC inhibitors are available on the market at present. In this study, we sought to create a new antibacterial agent without a hydroxamate moiety, which is a common component of the major LpxC inhibitors that have been reported to date and that may cause toxicity. As a result, a development candidate, TP0586532, was created that is effective against carbapenem-resistant Klebsiella pneumoniae and does not pose a cardiovascular risk.
